AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20844378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + 60% N2O
Number of subjects: 28
Study 20844378 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + 60% N2O
Number of subjects: 28
Study 18564797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam
Number of subjects: 672
Study 15992237 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 32
Study 15992237 — intervention group
Group type: COMPARATOR
Intervention: EUSOL dressing
Number of subjects: 32
Study 12888056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Eye Syndrome (DES) defined as clinically diagnosed DES or severe symptoms (dryness and irritation constantly or often)
Number of subjects: 39876
Study 12888056 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted prevalence of DES
Number of subjects: 39876
Study 12888056 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DES prevalence among different ethnic groups
Number of subjects: 39876
Study 12888056 — intervention group
Group type: COMPARATOR
Intervention: Education level and DES prevalence
Number of subjects: 39876
Study 12888056 — intervention group
Group type: COMPARATOR
Intervention: Geographic differences in DES prevalence
Number of subjects: 39876
Study 10329858 — intervention group
Group type: EXPERIMENTAL
Intervention: Estring (2 mg estradiol)
Number of subjects: 108
Study 10329858 — intervention group
Group type: COMPARATOR
Intervention: Control (no estrogen treatment)
Number of subjects: 108
Study 7498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% drops
Number of subjects: 17
Study 7498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pilocarpine 4% and Phenylephrine 10% drops
Number of subjects: 17
Study 7498565 — intervention group
Group type: COMPARATOR
Intervention: Control (Phenylephrine 10% drops alone)
Number of subjects: 17
Study 7498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 10% drops
Number of subjects: 17
Study 1685945 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine (10 mg daily)
Number of subjects: 60
Study 1685945 — intervention group
Group type: COMPARATOR
Intervention: beclomethasone dipropionate (100 micrograms in each nostril twice daily)
Number of subjects: 60
Study 7390386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipo-Merz retard (1 capsule/day)
Number of subjects: 98
Study 7390386 — intervention group
Group type: COMPARATOR
Intervention: Commercial combination product (1 capsule three times daily)
Number of subjects: 98
Study 30521757 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 37.5 mg
Number of subjects: 476
Study 30521757 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 75 mg
Number of subjects: 476
Study 30521757 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 476
Study 30521757 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 476
Study 30521757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study 30521757 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol (all doses except 37.5 mg)
Number of subjects: 476
Study 30521757 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 476
Study 27427786 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at a dosage of 90 μg/kg, administered in one to three doses for joint bleeding treatment.
Number of subjects: 177
Study 27427786 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered additional haemostatic medication (AHM) up to 48 hours after the first rFVIIa treatment.
Number of subjects: 177
Study 27427786 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to treatment initiation.
Number of subjects: 177
Study 27427786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and pain VAS assessments.
Number of subjects: 177
Study 25282123 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA Heartsaver CPR class augmented with a musical metronome (tempo of 100 beats/min)
Number of subjects: 0
Study 25282123 — intervention group
Group type: COMPARATOR
Intervention: AHA Heartsaver CPR class (standard CPR educational experience)
Number of subjects: 0
Study 25282123 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA Heartsaver CPR class augmented with a musical metronome
Number of subjects: 0
Study 23370083 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive suppression
Number of subjects: 224
Study 23370083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 224
Study 23370083 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 224
Study 21597261 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 2 mg (once nightly) for 4 weeks
Number of subjects: 73
Study 21597261 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 73
Study 21597261 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 73
Study 18626523 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous occlusion with lidocaine for 15 seconds (group I, n=50)
Number of subjects: 150
Study 18626523 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous occlusion with lidocaine for 30 seconds (group II, n=50)
Number of subjects: 150
Study 18626523 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous occlusion with lidocaine for 60 seconds (group III, n=50)
Number of subjects: 150
Study 16282583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone
Number of subjects: 80
Study 16282583 — intervention group
Group type: COMPARATOR
Intervention: Bone-hamstring-bone
Number of subjects: 80
Study 12510249 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 12510249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 0
Study 12510249 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (Angiotensin-receptor antagonist)
Number of subjects: 0
Study 12510249 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 12510249 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 10727543 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1650
Study 10727543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1650
Study 10727543 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1650
Study 1401438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel (FG; 1.1% NaF)
Number of subjects: 10
Study 1401438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride rinse (FR; 0.05% NaF)
Number of subjects: 10
Study 1401438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD; 0.24% NaF)
Number of subjects: 10
Study 1401438 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (PD)
Number of subjects: 10
Study 1401438 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time fluoride application
Number of subjects: 10
Study 1401438 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated parotid saliva sampling
Number of subjects: 10
Study 3998975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver nitrate prophylaxis
Number of subjects: 145
Study 3998975 — intervention group
Group type: COMPARATOR
Intervention: 1% tetracycline prophylaxis
Number of subjects: 145
Study 31256094 — intervention group
Group type: EXPERIMENTAL
Intervention: Versatile physiotherapy intervention conducted in accordance with European Physiotherapy Guideline for Parkinson's Disease (EPGPD), 16 one-hour therapy sessions (twice per week) over 10 weeks.
Number of subjects: 24
Study 31256094 — intervention group
Group type: EXPERIMENTAL
Intervention: Versatile physiotherapy intervention
Number of subjects: 24
Study 31256094 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 29739374 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Friendly Community Initiative (BFCI)
Number of subjects: 270
Study 26517202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441mg
Number of subjects: 622
Study 26517202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882mg
Number of subjects: 622
Study 26517202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 26517202 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (both doses)
Number of subjects: 622
Study 24894359 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom experiences with more instructional/emotional support
Number of subjects: 136
Study 22409596 — intervention group
Group type: EXPERIMENTAL
Intervention: USG‐PIVA (Ultrasound-guided peripheral venous access)
Number of subjects: 20
Study 22409596 — intervention group
Group type: COMPARATOR
Intervention: Blind technique (B)
Number of subjects: 20
Study 20219294 — intervention group
Group type: EXPERIMENTAL
Intervention: woman-focused intervention
Number of subjects: 455
Study 20219294 — intervention group
Group type: EXPERIMENTAL
Intervention: modified NIDA intervention
Number of subjects: 455
Study 20219294 — intervention group
Group type: COMPARATOR
Intervention: delayed-treatment control condition
Number of subjects: 455
Study 19030203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (PPI) treatment
Number of subjects: 114
Study 19030203 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care treatment (not according to study protocol)
Number of subjects: 114
Study 19030203 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 114
Study 16037177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine (300 microg in 2 mL)
Number of subjects: 60
Study 16037177 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 16037177 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (10 mg)
Number of subjects: 60
Study 12067088 — intervention group
Group type: EXPERIMENTAL
Intervention: CM acupuncture (real treatment)
Number of subjects: 29
Study 12067088 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control treatment)
Number of subjects: 29
Study 12067088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (real and sham)
Number of subjects: 29
Study 10066998 — intervention group
Group type: EXPERIMENTAL
Intervention: AX version of the Continuous Performance Test
Number of subjects: 0
Study 10066998 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop task
Number of subjects: 0
Study 10066998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical disambiguation task
Number of subjects: 0
Study 10066998 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 10066998 — intervention group
Group type: COMPARATOR
Intervention: Depressed controls
Number of subjects: 0
Study 8879853 — intervention group
Group type: EXPERIMENTAL
Intervention: Single large i.v. dose of gentamicin (10 mg/kg)
Number of subjects: 53
Study 8879853 — intervention group
Group type: COMPARATOR
Intervention: Standard multiple dose regimen of gentamicin (2.5 mg/kg i.v. stat and then divided doses)
Number of subjects: 53
Study 1638335 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg disulfiram
Number of subjects: 126
Study 1638335 — intervention group
Group type: COMPARATOR
Intervention: 100 mg vitamin C
Number of subjects: 126
Study 6542082 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (dosage titrated based on augmenter-reducer classification and pretreatment HR levels)
Number of subjects: 0
Study 6542082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31113542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of NICU light and noise levels during skin-to-skin care (SSC)
Number of subjects: 21
Study 31113542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine selected interventions to reduce light and noise levels
Number of subjects: 21
Study 29769026 — intervention group
Group type: EXPERIMENTAL
Intervention: CareWell program (multidisciplinary team meetings, proactive care planning, case management, medication reviews)
Number of subjects: 204
Study 29769026 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 204
Study 29769026 — intervention group
Group type: EXPERIMENTAL
Intervention: CareWell program
Number of subjects: 204
Study 27349717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination oral care (tooth brushing, chlorhexidine, and cold water)
Number of subjects: 39
Study 27349717 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard oral care regimen)
Number of subjects: 39
Study 24662027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated feline granulocyte colony-stimulating factor (PegFeG-CSF)
Number of subjects: 37
Study 24662027 — intervention group
Group type: COMPARATOR
Intervention: Feline granulocyte colony-stimulating factor (FeG-CSF)
Number of subjects: 37
Study 24662027 — intervention group
Group type: COMPARATOR
Intervention: Human granulocyte colony-stimulating factor (HuG-CSF)
Number of subjects: 37
Study 22042323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 100
Study 22042323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19913895 — intervention group
Group type: EXPERIMENTAL
Intervention: High CA-IX expression
Number of subjects: 166
Study 17874122 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra load on shoulders (10% of body mass)
Number of subjects: 24
Study 17874122 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra load around waists (10% of body mass)
Number of subjects: 24
Study 17874122 — intervention group
Group type: COMPARATOR
Intervention: Normal (baseline) condition
Number of subjects: 24
Study 16225571 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwi Omnicup
Number of subjects: 194
Study 16225571 — intervention group
Group type: COMPARATOR
Intervention: Standard vacuum cup (silastic or metal)
Number of subjects: 194
Study 12399701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy (cognitive-behavioural self-help booklet for health anxiety sufferers)
Number of subjects: 40
Study 12399701 — intervention group
Group type: COMPARATOR
Intervention: No bibliotherapy (control group)
Number of subjects: 40
Study 10827812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin suspension 1800 mg three times a day plus Omeprazole 20 mg twice a day (n = 10)
Number of subjects: 20
Study 10827812 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin pills 1800 mg three times a day plus Omeprazole twice a day (n = 10)
Number of subjects: 20
Study 10827812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin suspension
Number of subjects: 20
Study 10827812 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin pills
Number of subjects: 20
Study 10827812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) assessment in Munich sample
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) assessment in ECA sample
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of major depression in Munich
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of major depression in ECA study
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of dysthymia in Munich
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of dysthymia in ECA study
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment in institutionalized individuals
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment in females and oldest age cohort in ECA sample
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression in institutionalized individuals in Munich
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression in oldest age cohort in ECA study
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of dysthymia with sociodemographic factors
Number of subjects: 1229
Study 8527469 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess comorbidity of cognitive impairment and depression
Number of subjects: 1229
Study 1810681 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, a beta 1‐selective adrenergic blocker, administered for an unspecified duration.
Number of subjects: 0
Study 1810681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory electrocardiographic monitoring to measure ischemic episodes.
Number of subjects: 0
Study 1810681 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic impact of the diagnostic and therapeutic strategy.
Number of subjects: 0
Study 7113629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms/kg
Number of subjects: 45
Study 7113629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 6 micrograms/kg
Number of subjects: 45
Study 7113629 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 31619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech reception thresholds in spatially separated conditions (target at 0°, background noise at 90°)
Number of subjects: 39
Study 31619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech reception thresholds in collocated conditions (target and background at 0°)
Number of subjects: 39
Study 31619115 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stream segregation abilities in collocated conditions
Number of subjects: 39
Study 28922268 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling in addition to usual care physiotherapy
Number of subjects: 30
Study 28922268 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy alone (control)
Number of subjects: 30
Study 26383783 — intervention group
Group type: EXPERIMENTAL
Intervention: TV Commercial Stepping
Number of subjects: 58
Study 26383783 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 58
Study 24222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200-μg initially, then 100-μg due to side effects)
Number of subjects: 21
Study 24222260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23027480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless hemiarthroplasties (Group 1)
Number of subjects: 94
Study 23027480 — intervention group
Group type: COMPARATOR
Intervention: Cemented hemiarthroplasties (Group 2)
Number of subjects: 94
Study 23027480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless and cemented hemiarthroplasties
Number of subjects: 94
Study 19668780 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital random assignment (n=145)
Number of subjects: 328
Study 19668780 — intervention group
Group type: COMPARATOR
Intervention: Arrival by ambulance without prehospital random assignment (n=90)
Number of subjects: 328
Study 19668780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patients (n=93)
Number of subjects: 328
Study 19668780 — intervention group
Group type: COMPARATOR
Intervention: Community hospital (n=165)
Number of subjects: 328
Study 19668780 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI hospital (n=163)
Number of subjects: 328
Study 19161059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individual tooth brushing training every three months and guidance on oral health.
Number of subjects: 60
Study 19161059 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing training once a year (Control).
Number of subjects: 60
Study 19161059 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (experimental group).
Number of subjects: 60
Study 16080073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (initial dose of 100 mg, followed by 50 mg intravenously every 12 h)
Number of subjects: 1642
Study 16080073 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500/500 mg intravenously every 6 h)
Number of subjects: 1642
Study 16080073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 1642
Study 16080073 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 1642
Study 11985298 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive interviewer
Number of subjects: 81
Study 11985298 — intervention group
Group type: COMPARATOR
Intervention: Nonsupportive interviewer
Number of subjects: 81
Study 11985298 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Efficacy (mediator for older children)
Number of subjects: 81
Study 11985298 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting social support reserves
Number of subjects: 81
Study 9498728 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Naltrexone (NTX)
Number of subjects: 26
Study 9498728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9498728 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 26
Study 9098273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost applied in the evening
Number of subjects: 267
Study 9098273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost applied in the morning
Number of subjects: 267
Study 9098273 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol applied twice daily
Number of subjects: 267
Study 2230060 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 44
Study 2230060 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 44
Study 2230060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 375342 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 75 mg
Number of subjects: 0
Study 375342 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 150 mg
Number of subjects: 0
Study 375342 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 300 mg
Number of subjects: 0